Literature DB >> 18835214

The emergence of Nipah virus, a highly pathogenic paramyxovirus.

Michael K Lo1, Paul A Rota.   

Abstract

Nipah virus first emerged in Malaysia and Singapore between 1998 and 1999, causing severe febrile encephalitis in humans with a mortality rate of close to 40%. In addition, a significant portion of those recovering from acute infection had relapse encephalitis and long-term neurological defects. Since its initial outbreak, there have been numerous outbreaks in Bangladesh and India, in which the mortality rate rose to approximately 70%. These subsequent outbreaks were distinct from the initial outbreak, both in their epidemiology and in their clinical presentations. Recent developments in diagnostics may expedite disease diagnosis and outbreak containment, while progress in understanding the molecular biology of Nipah virus could lead to novel therapeutics and vaccines for this deadly pathogen.

Entities:  

Mesh:

Year:  2008        PMID: 18835214     DOI: 10.1016/j.jcv.2008.08.007

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  55 in total

1.  Characteristics of Nipah virus and Hendra virus replication in different cell lines and their suitability for antiviral screening.

Authors:  Mohamad Aljofan; Simon Saubern; Adam G Meyer; Glenn Marsh; Joanne Meers; Bruce A Mungall
Journal:  Virus Res       Date:  2009-01-29       Impact factor: 3.303

2.  Interferon signaling remains functional during henipavirus infection of human cell lines.

Authors:  Elena R Virtue; Glenn A Marsh; Lin-Fa Wang
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

3.  A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus.

Authors:  Bersabeh Tigabu; Lynn Rasmussen; E Lucile White; Nichole Tower; Mohammad Saeed; Alexander Bukreyev; Barry Rockx; James W LeDuc; James W Noah
Journal:  Assay Drug Dev Technol       Date:  2014-04       Impact factor: 1.738

Review 4.  Hendra and nipah infection: pathology, models and potential therapies.

Authors:  Frederic Vigant; Benhur Lee
Journal:  Infect Disord Drug Targets       Date:  2011-06

Review 5.  Flow Virometry: a Powerful Tool To Functionally Characterize Viruses.

Authors:  Roger Lippé
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

6.  Contribution of Human Lung Parenchyma and Leukocyte Influx to Oxidative Stress and Immune System-Mediated Pathology following Nipah Virus Infection.

Authors:  Olivier Escaffre; Tais B Saito; Terry L Juelich; Tetsuro Ikegami; Jennifer K Smith; David D Perez; Colm Atkins; Corri B Levine; Matthew B Huante; Rebecca J Nusbaum; Janice J Endsley; Alexander N Freiberg; Barry Rockx
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

7.  Nipah and Hendra Virus Nucleoproteins Inhibit Nuclear Accumulation of Signal Transducer and Activator of Transcription 1 (STAT1) and STAT2 by Interfering with Their Complex Formation.

Authors:  Akihiro Sugai; Hiroki Sato; Ikuyo Takayama; Misako Yoneda; Chieko Kai
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

8.  Infection of primary neurons mediated by nipah virus envelope proteins: role of host target cells in antiviral action.

Authors:  Aparna Talekar; Antonello Pessi; Matteo Porotto
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

9.  Use of monoclonal antibodies against Hendra and Nipah viruses in an antigen capture ELISA.

Authors:  Cheng-Feng Chiang; Michael K Lo; Paul A Rota; Christina F Spiropoulou; Pierre E Rollin
Journal:  Virol J       Date:  2010-06-03       Impact factor: 4.099

10.  Nipah virus infection: current scenario.

Authors:  D D Kulkarni; C Tosh; G Venkatesh; D Senthil Kumar
Journal:  Indian J Virol       Date:  2013-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.